Status:
COMPLETED
Effects of Neuromodulation and Cognitive Training for Suicide in Veterans (ENACTS)
Lead Sponsor:
VA Office of Research and Development
Conditions:
Suicide
Impulsivity
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Impaired executive function, such as impaired decision making and impulsivity, has been identified as an important contributor to the transition from suicidal ideation to suicide attempt. To address t...
Eligibility Criteria
Inclusion
- currently admitted into the MVAHCS Inpatient Psychiatric Unit
- at a heightened risk for suicide (defined as a positive screen on the VA Comprehensive Suicide Risk Evaluation (CSRE) at intake and/or a suicide attempt within the previous 12 months)
- able to complete procedures and tasks
Exclusion
- are unable to provide informed consent as determined by the Modified Dysken Tool
- have moderate/severe cognitive impairment as determined by the Mini-Mental State Examination (score 27)
- have contraindications for tDCS (history of seizures, metallic cranial plates/screws or implanted device, history of eczema on scalp)
- do not have a smartphone or device running Android or Apple iOS with which to download the mPRO EMA app
- have been involuntarily committed
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2025
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT05231213
Start Date
July 1 2022
End Date
March 31 2025
Last Update
May 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Minneapolis VA Health Care System, Minneapolis, MN
Minneapolis, Minnesota, United States, 55417-2309